Emerging drugs for irritable bowel syndrome

Expert Opinion on Emerging Drugs
Sylvie BradesiE A Mayer

Abstract

Irritable bowel syndrome (IBS) is one of the most common chronic gastrointestinal disorders, yet its pathophysiology is incompletely understood and pharmacological treatments remain unsatisfactory. Current therapeutic choices include a range of drugs aimed at normalising bowel habits, reducing pain or treating comorbid psychological symptoms. However, this individual symptom-targeted approach remains unsatisfactory in terms of global symptom relief and patient satisfaction. In the last decade, further characterisation of IBS pathophysiology has provided new and exciting targets at different levels of the brain-gut axis for the development of several candidate drugs. Advances in clinical trial design will help to evaluate these compounds in different IBS patient populations.

References

Jun 15, 1992·Annals of Internal Medicine·D A Drossman, W G Thompson
Jan 1, 1987·Scandinavian Journal of Gastroenterology. Supplement·N Hovdenak
Dec 1, 1986·Proceedings of the National Academy of Sciences of the United States of America·G M MaweM D Gershon
Mar 1, 1984·Digestive Diseases and Sciences·P A CannD Barends
Oct 1, 1994·Alimentary Pharmacology & Therapeutics·T PoynardJ C Chaput
Sep 1, 1993·Digestive Diseases and Sciences·A P WestonP B Miner
May 1, 1996·Scandinavian Journal of Gastroenterology·P S EfskindM H Vatn
Oct 1, 1996·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·S S Hegde, R M Eglen
Dec 24, 1997·Naunyn-Schmiedeberg's Archives of Pharmacology·P SanticioliC A Maggi
Feb 7, 1998·Neurogastroenterology and Motility : the Official Journal of the European Gastrointestinal Motility Society·M GuéL Buéno
Jul 1, 1998·The American Journal of Gastroenterology·S S RaoM J Chamberlain
Oct 13, 1998·Alimentary Pharmacology & Therapeutics·M DelvauxJ Frexinos
Aug 24, 1999·Gut·W G ThompsonS A Müller-Lissner
Mar 11, 2000·Digestive Diseases and Sciences·P WelganL Ma
Jun 23, 2000·European Journal of Pharmacology·R PatacchiniC A Maggi
Jun 29, 2000·Trends in Pharmacological Sciences·R Hill
Sep 30, 2000·Neurogastroenterology and Motility : the Official Journal of the European Gastrointestinal Motility Society·M O'SullivanC A O'Morain
Nov 4, 2000·The American Journal of Medicine·J L JacksonK Kroenke
Jan 11, 2001·The American Journal of Gastroenterology·M PimentelH C Lin
Feb 13, 2001·Gastroenterology·D FriedelR S Fisher
Feb 24, 2001·Alimentary Pharmacology & Therapeutics·M Camilleri
Feb 24, 2001·Alimentary Pharmacology & Therapeutics·T PoynardY Benhamou
Feb 24, 2001·American Journal of Physiology. Gastrointestinal and Liver Physiology·Y TachéL Wang
Mar 20, 2001·American Journal of Physiology. Gastrointestinal and Liver Physiology·E A MayerS V Coutinho
Mar 27, 2001·Annual Review of Pharmacology and Toxicology·S C StoutC B Nemeroff
Mar 29, 2001·Autonomic Neuroscience : Basic & Clinical·R A ReddixA Powell

❮ Previous
Next ❯

Citations

Apr 19, 2008·The New England Journal of Medicine·Emeran A Mayer
Nov 26, 2010·Annual Review of Medicine·Emeran A Mayer, Kirsten Tillisch
Feb 22, 2011·Journal of Psychosomatic Research·Michael JonesNicholas J Talley

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.